ClinicalTrials.gg
RecruitingNCT07750288Updated Sep 1, 2026

Role of Dyspnea in the Progression of Pediatric Acute Respiratory Distress Syndrome

An observational study in Pediatric Acute Respiratory Distress Syndrome (PARDS), sponsored by Universidad Nacional Andres Bello. Recruiting at 1 site in Chile. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Universidad Nacional Andres Bello · Observational

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
68
Ages
1 Month to 18 Years
Sex
All
01

Study summary

Pediatric acute respiratory distress syndrome (ARDS) is a life-threatening clinical syndrome, and dyspnea is its key symptom. Strenuous respiratory effort is a "second hit" for ARDS lungs, inducing changes in regional lung aeration and amplifying lung damage in preclinical studies, a phenomenon known as "patient self-inflicted lung injury". In a clinical setting, clinicians are concerned about the possible connection between dyspnea and ARDS progression based on indirect evidence, such as the worse outcomes associated with delayed intubation or failed weaning from mechanical ventilation. Dyspnea is hard to quantify due to its subjective nature. Still, it can be assessed through its interrelated and independent components: respiratory drive (neural stimuli), respiratory effort (muscle contraction), and work of breathing (energy expenditure).

This project aims to identify mechanical thresholds of dyspnea components to predict early ARDS progression and outcome. The role of respiratory effort is particularly relevant in three phases of ARDS where a transition between spontaneous and controlled ventilation occurs: 1) acute phase, when clinicians try to prevent mechanical ventilation (MV) through non-invasive support; 2) intermediate phase, transitioning from controlled to assisted MV; and 3) late phase, during weaning from MV. These transitions are challenging because it is difficult for clinicians to titrate adequate support and avoid both under- and over-assistance.

In critically ill children, there are no established thresholds for dyspnea components that predict ARDS progression, and it remains unknown whether regional changes in lung aeration can anticipate this clinical deterioration. This is particularly relevant because the oxygenation decline signals that ARDS progression has already occurred, leading to a less reversible condition.

The investigators will use and integrate advanced respiratory monitoring tools to quantify these components, including surface electromyography, occlusion maneuvers, and esophageal manometry. Additionally, electrical impedance tomography, recently adapted for pediatric use, will be employed to detect early changes in regional aeration. All of these tools are gold standards for each parameter and allow real-time, bedside measurements without adding invasiveness to usual care.

To test the hypothesis, the investigators will quantify respiratory drive, effort, work of breathing, and regional lung aeration throughout all transitional phases of pediatric ARDS. In the acute phase, drive will be assessed via spectral analysis of surface electromyography, and in intermediate and late phases, via airway occlusion pressure at 100 ms. Esophageal manometry will be used to measure effort (swings of esophageal pressure) and work of breathing (pressure-time product). Changes in regional aeration (overstretching, collapse, and heterogeneity) will be assessed using electrical impedance tomography.

The investigators will define mechanical thresholds and cut-off points for each dyspnea component that predict early ARDS progression and outcomes at each transitional phase. Based on the study results, the investigators envision the future development of algorithms to help guide safer transitions between spontaneous and controlled ventilation, to improve outcomes, and prevent residual morbidity. The interdisciplinary team of clinicians and biomedical engineers will work to customize respiratory care in critically ill children, optimizing ventilatory assistance across disease stages.

02

Conditions studied

  • Pediatric Acute Respiratory Distress Syndrome (PARDS)

Keywords

  • respiratory effort
  • monitoring
  • surface electromyography
  • esophageal manometry
03

In context

Respiratory Distress Syndrome

1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 283 are open to participants now.

This study's planned enrollment of 68 is below the median of 100 across 475 observational studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

Universidad Nacional Andres Bello is the lead sponsor of 23 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children younger than 18 years old with a diagnosis of pediatric ARDS,

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children younger than 18 years old.
  • Diagnosis of pediatric ARDS, as defined by the 2023 Pediatric Acute Lung Injury Consensus Conference (PALICC2).
  • Consent to participate given by legal guardians.

Exclusion criteria

Exclusion Criteria:

  • Tracheostomy.
  • Neuromuscular disease.
  • Uncorrected congenital heart disease.
  • to esophageal catheter (choanal atresia, esophageal issues, recent esophageal surgery, etc.) or EIT (pacemakers, defibrillators, and unstable fractures).
  • Emergency intubation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
68 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • PARDS/acute phase

    PARDS patients under noninvasive respiratory support

    Device: Noninvasive respiratory support

  • PARDS/intermediate phase

    Transition from controlled to assisted MV

    Device: Transition from controlled to assisted mechanical ventilation

  • PARDS/ late phase

    Weaning from MV

    Device: Weaning from mechanical ventilation

Interventions

  • DeviceNoninvasive respiratory support

    sEMG of respiratory muscles, esophageal manometry, and electrical impedance tomography

  • DeviceTransition from controlled to assisted mechanical ventilation

    sEMG of respiratory muscles, esophageal monitoring, and electrical impedance tomography

  • DeviceWeaning from mechanical ventilation

    sEMG of respiratory muscles, esophageal monitoring, and electrical impedance tomography

06

What researchers measure

Primary outcomes

  1. Success or Failure of the Intervention

    Oxygenation decline (20% drop from baseline) or clinical signs of ventilatory overload. The outcome of the intervention will be determined by the attending physician. Measurements derived from the use of advanced respiratory monitoring tools will not be used to define the clinical outcome.

    Time frame: From enrollment to the end of respiratory support, with a maximal follow-up of 30 days.

Secondary outcomes

  1. Early changes in regional lung aeration, perfusion, or ventilation/perfusion mismatch

    Assesed by electrical impedance tomography

    Time frame: From enrollment to the end of the respiratory support, with a maximal follow-up of 30 days.

  2. Ventilator-free days

    Time frame: From enrollment to the end of respiratory support, with a maximal follow-up of 30 days.

Other outcomes

  1. The correlation between surrogates and gold-standard assessments of respiratory drive and effort

    Time frame: From enrollment to the end of respiratory support, with a maximal follow-up of 30 days.

07

Study locations

1 of 1 sites recruiting
  • Hospital El Carmen Dr. Luis Valentin Ferrada
    Santiago, Chile
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized and encrypted records of advanced pulmonary function monitoring could be shared with other research groups whose main research lines are PARDS/ respiratory effort/ mechanical ventilation.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: From January 1st, 2027 to December 31st, 2031

Access criteria: By request to the principal investigator, other research groups whose main research lines are PARDS/ respiratory effort/ mechanical ventilation.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07750288
Lead sponsor
Universidad Nacional Andres Bello
Collaborators
Pontificia Universidad Catolica de Chile, Universidad de los Andes, Chile
Responsible party
Pablo Cruces (MD; Pediatric Critical Care, Universidad Nacional Andres Bello) — Principal investigator
First posted
Aug 6, 2026
Start date
Jul 13, 2026
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Sep 1, 2026

Study contacts

Pablo Cruces, Full Professor
Contact
pablo.cruces@unab.cl
(56)990200810

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion